An extra Shingrix dose for transplant patients
Part of Infections clinical trials.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost protection in people who have had a solid-organ transplant. If you already received both doses of Shingrix after your transplant, this trial will give you an additional dose to see if it further strengthens your immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have received a solid-organ transplant and it has been at least 6 months since the transplant
- You have already gotten both doses of the Shingrix shingles vaccine, and it has been at least 6 months since the second dose
- If you had a treated episode of organ rejection, it must have been at least 8 weeks ago (or 6 months if you received certain strong immune-suppressing drugs like rituximab or alemtuzumab)
- You are not currently sick with a fever or active infection, and you have no known allergy to the vaccine components
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
This study tests the shingles vaccine in young adults who have had a solid organ transplant (like a kidney or liver) more than a year ago. The goal is to see if the vaccine works well and is safe for people on stable anti-rejection medicines.
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.
Hear when a new Zoster; Herpes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.